SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending amid excitement around its potential role in powering AI data centers and a recent announcement regarding a nuclear fuel recycling facility. The community is actively discussing the stock's high valuation relative to its lack of revenue, with some viewing it as a speculative opportunity and others as a potential short. Bullish sentiment is fueled by the growing need for energy to support AI and the company's potential to capitalize on this demand.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

RCAT is trending due to the announcement that its Black Widow drone system has been approved and added to the NATO Support and Procurement Agency catalog, a move seen as a significant step towards potential contracts and revenue. The community is actively discussing the implications of this approval, with some expressing optimism about future growth and others remaining cautious until actual purchase orders are secured. Broader discussions include comparisons to other drone companies and the potential impact on the defense sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla $TSLA is trending as traders discuss Elon Musk's recent $1 billion stock purchase and its impact on the stock's momentum. The community is debating whether this is a vote of confidence or a manipulation tactic, while also eyeing potential catalysts such as robotaxi developments and future AI advancements. Overall sentiment seems to be mixed, some seeing potential for the stock to reach new highs while others stay cautious.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as community members discuss the potential impact of their technology being showcased in a Ducati motorcycle at IAA Mobility, viewing it as a signal of progress. Bullish sentiment seems to be building due to confidence in the company's execution and potential partnerships, while some investors are focusing on upcoming catalysts and revenue streams. The community is actively debating the significance of this demonstration and its implications for the broader EV battery landscape.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is trending due to disappointing earnings, with revenue and EPS missing estimates, sparking discussions about its financial health. The community is focused on the potential for a continued downturn, while some are looking at its low price with high short interest and institutional ownership as an opportunity for a potential short squeeze. Broader concerns about consumer discretionary spending and the company's strategic direction are also being discussed.

Helius Medical Technologies, Inc. is a neurotech company in the medical device industry that focuses on neurological wellness. The firm develops, licenses and acquires non-invasive platform technologies that amplify the brain’s ability to heal itself and reduce symptoms of neurological disease or trauma. It engages in the development of the investigational portable neuromodulation stimulator, that delivers neurostimulation via the tongue which has been shown in clinical studies to enhance the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. The company was founded on March 13, 2014 and is headquartered in Newtown, PA.

Helius Medical Technologies Inc - Ordinary Shares - Class A

Helius Medical Technologies Inc

HSDT is trending following news of raising over $500M in funding, with plans to launch a SOL-backed treasury vehicle, leading to significant price movement. The community is actively discussing potential dilution, short squeezes, and future price targets, while also debating the company's shift from medical technologies to cryptocurrency ventures. Some traders are drawing parallels to other high-flying stocks and anticipating further gains, while others caution about potential risks and market manipulation.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

$WAGMI.X is trending due to strong community support and its association with the Solana ecosystem, with many highlighting the acronym's positive message: We're All Gonna Make It. Community members are actively promoting the coin's potential, emphasizing its strong cultural relevance and comparing it to previous meme coin successes like $SHIB and $DOGE.

Lyft, Inc. engages in the provision and management of an online social rideshare community platform. It offers access to a network of shared bikes and scooters for shorter rides and first mile and last-mile legs of multimodal trips, information about nearby public transit routes, and Lyft Rentals to offer riders a view of transportation options when planning any trip. The company was founded by Marcus Cohn, John Zimmer, Rajat Suri, Matt van Horn, and Logan Green in 2007 and is headquartered in San Francisco, CA.

Lyft Inc - Ordinary Shares Cls A

Lyft Inc

LYFT is trending as community members discuss potential reasons for its recent price movement, including speculation about a possible buyout or short squeeze. Some traders are pointing to options activity and technical indicators, while others highlight the company's improving fundamentals and expansion plans. Overall, the conversation reflects uncertainty coupled with speculation about the factors driving LYFT's current performance.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending as community members discuss its potential shift towards AI/HPC, drawing comparisons to other miners already capitalizing on the sector. Bullish investors express optimism about the company's long-term prospects and potential for a short squeeze, while others voice frustration over its recent performance relative to peers and concerns about management decisions.

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics is trending following news of a licensing agreement with Novartis, potentially worth billions, focused on developing molecular glue degraders. The community is discussing the deal's implications for the stock's valuation, short squeeze potential, and future buyout possibilities, while also weighing potential risks and consolidation patterns. Some traders are pointing to the relatively small float as a catalyst for significant price movement.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Context Therapeutics Inc. rose over&nbsp;7% in Wednesday's pre-market trading after JMP Securities initiated coverage with an 'Outperform' rating and a price target of $4.&nbsp;The brokerage's target implies a near quadrupling from the stock's previous close and has fueled bullish sentiment among retail investors.In its research note, JMP highlighted Context's focus on developing next-generation T-cell-engaged bispecific antibody therapies for solid tumors.&nbsp;The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which the analyst described as "innovative."&nbsp;JMP also praised the management team's business development acumen in assembling a pipeline that it believes is “worth more than the sum of its parts.”Retail chatter on Stocktwits mirrored the analyst's enthusiasm, with one user predicting a move to $6 and another noting the stock could "come back in a hurry" after a period of limited news flow.<stembedurl>https://stocktwits.com/Leonkika/message/599089608</stembedurl><stembedurl>https://stocktwits.com/claybridge/message/598957638</stembedurl>Context Therapeutics' lead program, CTIM-76, is poised to enter clinical trials soon.&nbsp;According to D. Boral Capital, which issued a ‘Buy’ rating and a $9 price target in November, CTIM-76 targets Claudin 6, a tumor marker broadly expressed in solid tumors like gynecologic and testicular cancers but largely absent in healthy adult tissues.&nbsp;This specificity makes it a promising therapeutic target, the brokerage said.Context’s stock has lost over 8% over the past year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Hand holding test tube over stock data on computer monitor. | Image source: Getty Images

Context Therapeutics Stock Jumps Pre-Market On Analyst's Near 4x Upside View: Retail Pins High Hopes Too

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”

Equity

The micro-cap biotech is building a portfolio of in-licensed clinical-stage TCE bispecific antibodies, which JMP described as "innovative”


Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment PR Newswire VANCOUVER, BC, Dec. 26, 2024 USA News...

Context Therapeutics submits IND application for CTIM-76

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

Important Regulatory Milestone Supports Next Phase of CTIM-76 DevelopmentPHILADELPHIA, April 01, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ( Context or the Company ) (Nasdaq: CNTX), a...

Context Therapeutics Advances Cancer Trial with FDA Submission

Context Therapeutics (CNTX) has provided an update. Context Therapeutics Inc. has announced the submission of an IND application to the FDA for a P...

Context Therapeutics (NASDAQ:CNTX) Price Target Cut to $4.00

Context Therapeutics (NASDAQ:CNTX  Free Report) had its target price lowered by HC Wainwright from $5.00 to $4.00 in a research report sent to investors on Thursday, Benzinga reports. HC...

Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics' Strategic Drug Positioning

Maxim Group analyst Jason McCarthy maintained a Buy rating on Context Therapeutics (CNTX Research Report) yesterday and set a price target of $4...

Context Therapeutics expects cash to fund operations into late 2024

Context Therapeutics reports 2023 EPS ($1.50) vs. (93c) last year

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations...

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Context Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

Current Price	$0.8118
Prev Close	$0.835
Open	$0.86
Dividend Yield	0.00%
50-Day Moving Average	$0.789
Beta	1.05
Avg. Volume	168,068.38
PE Ratio	-2.11

52-Week High	$2.59
52-Week Low	$0.49
Market Capitalization	$74.9M
EPS (Annual)	-$0.4575
Price to Book	0.91
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

CNTX
Context Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Latest CNTX News

CNTX Context Therapeutics Inc